Infinity Pharmaceuticals Revenue and Competitors

Boston, MA USA

Location

$538M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Infinity Pharmaceuticals's estimated annual revenue is currently $1.8M per year.(i)
  • Infinity Pharmaceuticals's estimated revenue per employee is $5,014
  • Infinity Pharmaceuticals's total funding is $538M.
  • Infinity Pharmaceuticals's current valuation is $121.1M. (January 2022)

Employee Data

  • Infinity Pharmaceuticals has 367 Employees.(i)
  • Infinity Pharmaceuticals grew their employee count by -4% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.6M237-4%N/AN/A
#3
$22.3M11152%N/AN/A
#4
$23.9M1198%$113MN/A
#5
$0.3M30%N/AN/A
#6
$11.9M5923%N/AN/A
#7
$1.8M367-4%$538MN/A
#8
$48.6M24221%N/AN/A
#9
$21.4M130-13%$525.5MN/A
#10
$11.6M901%$506.4MN/A
Add Company

Infinity Pharmaceuticals, Inc., based in Boston, Massachusetts, was founded in 2001 by world leaders in chemistry, genomic biology, medicine, software, and business. The company is committed to improving human health by changing drug discovery to bring important new medicines to patients. Infinity's initial drug discovery efforts are focused on cancer, metabolic disorders, infectious disease and inflammatory disease.

keywords:N/A

$538M

Total Funding

367

Number of Employees

$1.8M

Revenue (est)

-4%

Employee Growth %

$121.1M

Valuation

N/A

Accelerator

Infinity Pharmaceuticals News

2022-04-19 - Infinity Pharmaceuticals (INFI) Set to Announce Quarterly ...

Infinity Pharmaceuticals (NASDAQ:INFI – Get Rating) will post its quarterly earnings results after the market closes on Tuesday, May 3rd.

2022-03-30 - Infinity Pharmaceuticals Announces Inducement Grants Under ...

(“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-...

2022-03-22 - Infinity Pharmaceuticals stock soars 25% after FY21 revenue ...

Shares of Infinity Pharmaceuticals (INFI +26.6%) rose after reporting better-than-expected FY revenue from royalties.

2020-01-09 - Infinity Pharmaceuticals Raises $20 Million

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a $20 million non-dilutive asset-backed financing with BVF Partners L.P., Infinity’s largest shareholder. This investment by BVF entails no equity to be issued by Infinity and has its sole recourse i ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$79.9M3688%$174M
#2
$96.9M36948%N/A
#3
$83.5M37133%N/A
#4
$68.9M380N/AN/A
#5
$158M38961%N/A

Infinity Pharmaceuticals Executives


NameTitle
Adelene PerkinsChair, President and CEO
Seth TaskerChief Business Officer
Brian SchwartzConsulting Chief Physician
Stephane PelusoChief Scientific Officer
Joseph McPhersonVice President, Facilities Operations
Bea IveyPresident
Adelene PerkinsChair, President and CEO
Don D'AntonioPresident
Melissa HackelVice President of Finance
James HamVP Finance
Lawrence BlochPresident
Jennifer RobertsVP, Clinical Development Operations
John LeeVice President